Arbutus Biopharma Corp
NASDAQ: ABUS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Lindsay Androski
- Employees
- 19
- Headquarters
- Warminster, United States
- IPO year
- 2007
- Market cap
- $881.0M
- Website
- http://www.arbutusbio.com
Loading ABUS…
Loading profile data…Frequently asked questions about ABUS
What does Arbutus Biopharma Corp (ABUS) do?
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses...
Where does ABUS trade?
Arbutus Biopharma Corp (ABUS) trades on the NASDAQ.
What sector is ABUS in?
Arbutus Biopharma Corp (ABUS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Arbutus Biopharma Corp?
Lindsay Androski is the chief executive officer of Arbutus Biopharma Corp (ABUS).
Where is Arbutus Biopharma Corp headquartered?
Arbutus Biopharma Corp is headquartered in United States.
Does ABUS pay a dividend?
Arbutus Biopharma Corp (ABUS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ABUS go public?
Arbutus Biopharma Corp (ABUS) completed its initial public offering in 2007.